TY - JOUR
T1 - Association analysis of GRM2 and HTR2A with methamphetamine-induced psychosis and schizophrenia in the Japanese population
AU - Tsunoka, Tomoko
AU - Kishi, Taro
AU - Kitajima, Tsuyoshi
AU - Okochi, Tomo
AU - Okumura, Takenori
AU - Yamanouchi, Yoshio
AU - Kinoshita, Yoko
AU - Kawashima, Kunihiro
AU - Naitoh, Hiroshi
AU - Inada, Toshiya
AU - Ujike, Hiroshi
AU - Yamada, Mitsuhiko
AU - Uchimura, Naohisa
AU - Sora, Ichiro
AU - Iyo, Masaomi
AU - Ozaki, Norio
AU - Iwata, Nakao
N1 - Funding Information:
We thank Ms. M. Miyata, and Ms. S. Ishihara for their technical support. This work was supported in part by research grants from the Japan Ministry of Education, Culture, Sports, Science and Technology , the Ministry of Health, Labor and Welfare, and the Health Sciences Foundation (Research on Health Sciences focusing on Drug Innovation) .
PY - 2010/5
Y1 - 2010/5
N2 - Background: Abnormalities in glutaminergic neural transmission have been suggested to be involved in the pathogenesis of schizophrenia. A recent study reported that alterations in the 5-HT2A-mGluR2 complex may be involved in neural transmission in the schizophrenic cortex. In addition, methamphetamine-induced psychosis is thought to be similar to schizophrenia. Therefore, we conducted a case-control study with Japanese samples (738 schizophrenia patients, 196 methamphetamine-induced psychosis patients, and 802 controls) to evaluate the association and interaction between GRM2, HTR2A and schizophrenia. Methods: We selected three 'tagging SNPs' in GRM2, and two biologically functional SNPs in HTR2A (T102C and A1438G), for the association analysis. Results: We detected a significant association between methamphetamine-induced psychosis and GRM2 in a haplotype-wise analysis, but not HTR2A. We did not detect an association between GRM2 or HTR2A and schizophrenia. In addition, no interactions of GRM2 and HTR2A were found in methamphetamine-induced psychosis or schizophrenia. We did not detect any novel polymorphisms in GRM2 when we performed a mutation search using methamphetamine-induced psychosis samples. Conclusion: Our results suggested that GRM2 may play a role in the pathophysiology of methamphetamine-induced psychosis but not schizophrenia in the Japanese population. A replication study using larger samples or samples of other populations will be required for conclusive results.
AB - Background: Abnormalities in glutaminergic neural transmission have been suggested to be involved in the pathogenesis of schizophrenia. A recent study reported that alterations in the 5-HT2A-mGluR2 complex may be involved in neural transmission in the schizophrenic cortex. In addition, methamphetamine-induced psychosis is thought to be similar to schizophrenia. Therefore, we conducted a case-control study with Japanese samples (738 schizophrenia patients, 196 methamphetamine-induced psychosis patients, and 802 controls) to evaluate the association and interaction between GRM2, HTR2A and schizophrenia. Methods: We selected three 'tagging SNPs' in GRM2, and two biologically functional SNPs in HTR2A (T102C and A1438G), for the association analysis. Results: We detected a significant association between methamphetamine-induced psychosis and GRM2 in a haplotype-wise analysis, but not HTR2A. We did not detect an association between GRM2 or HTR2A and schizophrenia. In addition, no interactions of GRM2 and HTR2A were found in methamphetamine-induced psychosis or schizophrenia. We did not detect any novel polymorphisms in GRM2 when we performed a mutation search using methamphetamine-induced psychosis samples. Conclusion: Our results suggested that GRM2 may play a role in the pathophysiology of methamphetamine-induced psychosis but not schizophrenia in the Japanese population. A replication study using larger samples or samples of other populations will be required for conclusive results.
UR - http://www.scopus.com/inward/record.url?scp=77952671499&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952671499&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2010.03.002
DO - 10.1016/j.pnpbp.2010.03.002
M3 - Article
C2 - 20211215
AN - SCOPUS:77952671499
SN - 0278-5846
VL - 34
SP - 639
EP - 644
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
IS - 4
ER -